1. Home
  2. OLMA vs ENOV Comparison

OLMA vs ENOV Comparison

Compare OLMA & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Olema Pharmaceuticals Inc.

OLMA

Olema Pharmaceuticals Inc.

HOLD

Current Price

$24.95

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Enovis Corporation

ENOV

Enovis Corporation

HOLD

Current Price

$22.36

Market Cap

1.6B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
OLMA
ENOV
Founded
2006
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Fluid Controls
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.6B
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
OLMA
ENOV
Price
$24.95
$22.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
8
Target Price
$41.14
$48.13
AVG Volume (30 Days)
1.3M
1.2M
Earning Date
03-17-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,233,266,000.00
Revenue This Year
N/A
$9.22
Revenue Next Year
N/A
$4.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
11.57
52 Week Low
$2.86
$21.00
52 Week High
$36.26
$47.26

Technical Indicators

Market Signals
Indicator
OLMA
ENOV
Relative Strength Index (RSI) 45.25 41.26
Support Level $24.91 $21.72
Resistance Level $27.13 $23.37
Average True Range (ATR) 1.78 1.10
MACD -0.16 0.10
Stochastic Oscillator 40.52 38.73

Price Performance

Historical Comparison
OLMA
ENOV

About OLMA Olema Pharmaceuticals Inc.

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

About ENOV Enovis Corporation

Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.

Share on Social Networks: